Results 1 to 10 of about 18,762 (211)

Mechanism of baricitinib supports artificial intelligence‐predicted testing in COVID ‐19 patients [PDF]

EMBO Molecular Medicine, 2020
Baricitinib is an oral Janus kinase (JAK)1/JAK2 inhibitor approved for the treatment of rheumatoid arthritis (RA) that was independently predicted, using artificial intelligence (AI) algorithms, to be useful for COVID‐19 infection via proposed anti ...
Justin Stebbing, Venkaṭesh Krishnan, Silvia Ottaviani   +2 more
exaly   +5 more sources

Baricitinib for atopic dermatitis patients who responded inadequately to dupilumab treatment: First daily practice results [PDF]

JEADV Clinical Practice, 2022
Background Baricitinib is the first JAK inhibitor registered for the treatment of moderate‐to‐severe atopic dermatitis (AD). Efficacy and safety were shown in clinical trials, but daily practice data is sparse.
Linde deWijs, Corine Schreurs, Anne Schlösser, Tamar Nijsten, Dirk Jan Hijnen   +4 more
doaj   +5 more sources

Comparative effectiveness of improvement in pain and physical function for baricitinib versus adalimumab, tocilizumab and tofacitinib monotherapies in rheumatoid arthritis patients who are naïve to treatment with biologic or conventional synthetic disease-modifying antirheumatic drugs: a matching-adjusted indirect comparison [PDF]

RMD Open, 2020
Objective To compare improvement in pain and physical function for patients treated with baricitinib, adalimumab, tocilizumab and tofacitinib monotherapy from randomised, methotrexate (MTX)-controlled trials in conventional synthetic disease-modifying ...
P Emery, M Van de Laar, R Fleischmann, B Fautrel, P C Taylor, I De La Torre, B Zhu, F De Leonardis, C L Kannowski, C Nicolay, Z Kadziola   +10 more
doaj   +7 more sources

Baricitinib ameliorates skin fibrosis via direct fibroblast suppression and endothelial exosome-mediated paracrine signaling [PDF]

Arthritis Research & Therapy
Background Novel therapies are urgently needed for diffuse cutaneous systemic sclerosis (dcSSc). Aberrant JAK/STAT signaling drives fibrosis, but JAK inhibitors’ effects on vascular pathology and potential synergy with endothelial-derived exosomes remain
Zhanying Hou, Xiufeng Zhao, Fang Liu, Shi Xu   +3 more
doaj   +2 more sources

Janus Kinase Inhibitor Baricitinib Modulates Human Innate and Adaptive Immune System

Frontiers in Immunology, 2018
The purpose of this study was to elucidate the mechanism of action of baricitinib on Janus kinase (JAK)/signal transducer and activator of transcription (STAT) signaling, which involves in human innate and adaptive immune system.
Satoshi Kubo, Shingo Nakayamada, Yukihiro Kitanaga   +2 more
exaly   +3 more sources

Reversal of Alopecia Areata Following Treatment With the JAK1/2 Inhibitor Baricitinib

EBioMedicine, 2015
Background: Alopecia areata (AA) is an autoimmune disease resulting in hair loss with devastating psychosocial consequences. Despite its high prevalence, there are no FDA-approved treatments for AA.
Ali Jabbari, Zhenpeng Dai, Jane E Cerise   +2 more
exaly   +3 more sources

PERFECTRA: a pragmatic, multicentre, real-life study comparing treat-to-target strategies with baricitinib versus TNF inhibitors in patients with active rheumatoid arthritis after failure on csDMARDs [PDF]

RMD Open
Objective To compare the effectiveness of a strategy administering baricitinib versus one using TNF-inhibitors (TNFi) in patients with rheumatoid arthritis (RA) after conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) failure in a ...
Mart van de Laar, Tim Jansen, A Willemze, Y P M Goekoop-Ruiterman, Reinhard Bos, Eric-Jan Kroot, Celine J van de Laar, Martijn A H Oude Voshaar, Peter ten Klooster, Danyta I Tedjo, Grada A Versteeg   +10 more
doaj   +3 more sources

Baricitinib as Treatment Option for Corona Virus Disease-19: a Literature Review

Jurnal Kedokteran Diponegoro, 2022
Background : Treatment of COVID-19 using IL-6 inhibitors, including Sarilumab or Tocilizumab, significantly decreased mortality risk. Though, Remdesivir therapy gave benefits, morbidity and mortality remained high.
Thomas Handoyo, Nur Farhanah, Gianina Dinda Pamungkas   +2 more
doaj   +1 more source

Baricitinib decreases anti-dsDNA in patients with systemic lupus erythematosus: results from a phase II double-blind, randomized, placebo-controlled trial

Arthritis Research & Therapy, 2022
Background Patients with systemic lupus erythematosus (SLE) have substantial unmet medical need. Baricitinib is a Janus kinase (JAK)1 and 2 inhibitor that was shown to have therapeutic benefit in patients with SLE in a phase II clinical trial.
Thomas Dörner, Ronald F. van Vollenhoven, Andrea Doria, Bochao Jia, Jorge A. Ross Terres, Maria E. Silk, Stephanie de Bono, Peter Fischer, Daniel J. Wallace   +8 more
doaj   +1 more source

Evaluation of VTE, MACE, and Serious Infections Among Patients with RA Treated with Baricitinib Compared to TNFi: A Multi-Database Study of Patients in Routine Care Using Disease Registries and Claims Databases

Rheumatology and Therapy, 2022
Introduction The aim of this work is to evaluate baricitinib safety with respect to venous thromboembolism (VTE), major adverse cardiovascular events (MACE), and serious infection relative to tumor necrosis factor inhibitors (TNFi) in patients with ...
Claudia A. Salinas, Anthony Louder, Jennifer Polinski, Tancy C. Zhang, Hannah Bower, Syd Phillips, Yufei Song, Emaan Rashidi, Rafia Bosan, Hsiu-Ching Chang, Nicole Foster, Bernice Gershenson, Hisashi Yamanaka, Mitsumasa Kishimoto, Yoshiya Tanaka, Peter Fischer, Baojin Zhu, Douglas Faries, Xiaodan Mai, Brett T. Doherty, Angela Grelaud, Nicolas H. Thurin, Johan Askling, Walter Deberdt, the B023 Study Consortium   +24 more
doaj   +1 more source